Free Newsletter
Enbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a boxed warning about tuberculosis and other life-threatening illness; the label states that patients using the drug have contracted infections that led to hospitalization and death. The drug is primarily used to treat psoriasis, but also is used for rheumatoid arthritis and other autoimmune disorders.
Amgen and Wyeth co-market Enbrel in the U.S. and Canada. The drug posted $3.2 billion in sales in 2007.
- see the CNN Money coverage
ALSO: According to the latest CEO ranking by Forbes magazine, which measured performance against pay for 175 company chiefs, Amgen's Kevin Sharer came in near the bottom of the barrel, at 169th. Report
Related Articles:
Alzheimer's: A new indication for Enbrel?
Enbrel gets 'black box' infection warning
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: